Latest Healthcare Research Reports

Tag: eosinophilic asthma market size

  • Eosinophilic Asthma Market Size Projected To Increase From $3.7 Billion To $6.92 Billion During The Forecast Period

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Eosinophilic Asthma Market Size, Value And Growth Trends Through 2030

    The market for eosinophilic asthma experienced considerable expansion lately. Projections indicate a rise from $3.16 billion in 2025 to $3.71 billion in 2026, reflecting a compound annual growth rate of 17.4%. This upward trajectory is underpinned by factors observed throughout the historical period, including diminished responsiveness to inhaled corticosteroids, an increasing incidence of asthma, the successful identification of eosinophil biomarkers, a higher number of hospital admissions for asthma-related issues, and the overall impact of chronic respiratory diseases.

    The market for eosinophilic asthma is poised for substantial expansion in the upcoming years, projected to reach $6.92 billion by 2030, driven by a compound annual growth rate of 16.9%. This anticipated surge is fueled by several key factors, including advancements in precise asthma treatment modalities, the broadening of biologic drug development pipelines, the increasing utilization of biomarker-driven diagnostic approaches, the growing emphasis on personalized respiratory care strategies, and the proliferation of specialized treatment centers. Furthermore, critical trends shaping this market over the forecast period encompass the accelerating embrace of biologic therapies, a heightened concentration on identifying and managing severe asthma phenotypes, escalating demand for immunotherapies specifically designed for targeted treatment, the continuous development of dedicated respiratory clinics, and a significant focus on mitigating the frequency of asthma exacerbations.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

    Eosinophilic Asthma Market Growth Factors Supporting Long-Term Expansion

    An increase in smoking behaviors is anticipated to be a primary driver for the expansion of the eosinophilic asthma market. These behaviors encompass the consistent patterns of tobacco product consumption, including how often, under what circumstances, and for how long individuals smoke, frequently shaped by psychological, societal, and environmental influences. Escalating smoking rates can be attributed to various elements, such as heightened stress levels, strategic promotional efforts by tobacco corporations, insufficient knowledge regarding health hazards, and the cultural acceptance of smoking in specific communities. Treatments for eosinophilic asthma, which focus on mitigating airway inflammation and enhancing respiratory capacity, can provide an impetus for individuals to quit smoking by addressing the pulmonary difficulties that often perpetuate the habit. As an illustration, data from the Office for National Statistics in the UK indicated that in November 2025, the prevalence of e-cigarette use among women in Great Britain rose from 8.5% in 2023 to 10.0% in 2024. Moreover, the highest rates of daily e-cigarette use were observed in Great Britain among individuals aged 25 to 34 and 35 to 49 years, registering 9.3% and 9.5% respectively, with an upward trend noted for both demographics from 2023. Consequently, the growing incidence of smoking is a significant factor fueling the eosinophilic asthma market.

    Eosinophilic Asthma Market Segment Landscape And Growth Potential

    The eosinophilic asthma market covered in this report is segmented –

    1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

    2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

    3) By End User: Hospitals, Clinics, Other End Users

    Subsegments:

    1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

    2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

    Eosinophilic Asthma Market Industry Trends Shaping Future Revenue Growth

    Leading entities within the eosinophilic asthma marketplace are focused on creating novel therapeutics aimed at specific immunological pathways, thereby mitigating inflammation and enhancing patient results through tailored interventions. Monoclonal antibodies are essentially engineered proteins, designed to replicate the body’s natural defense mechanisms against illnesses caused by agents like viruses and bacteria; their creation involves combining an antibody-producing cell with a cancerous cell, facilitating the mass production of identical antibodies. Highlighting this trend, AstraZeneca plc, a pharmaceutical giant from the UK, reported in August 2024 that its drug, Fasenra, had secured approval from China’s National Medical Products Administration for managing severe eosinophilic asthma. This particular therapy is designated for individuals suffering from severe eosinophilic asthma, a condition distinguished by elevated eosinophil counts, which often exacerbates asthmatic symptoms and inflammation. As a monoclonal antibody, Fasenra works by targeting and reducing eosinophils via a distinct method, strengthening the body’s immune response by attaching to the IL-5 receptor on eosinophils, which consequently lowers their concentration in both the bloodstream and bodily tissues. The administration schedule includes an initial dose escalation period followed by ongoing maintenance treatments, typically involving injections administered every four weeks for the initial three doses, after which the interval extends to every eight weeks.

    Eosinophilic Asthma Market Competitive Landscape: Who Are The Leading Companies?

    Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

    Access The Complete Eosinophilic Asthma Market Report:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Eosinophilic Asthma Market Largest Region: Which Geography Holds The Highest Market Share?

    North Americawas the largest region in the eosinophilic asthma market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Eosinophilic Asthma Market Size Projected To Increase From $3.7 Billion To $6.92 Billion During The Forecast Period

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Eosinophilic Asthma Market Size, Value And Growth Trends Through 2030

    The market for eosinophilic asthma experienced considerable expansion lately. Projections indicate a rise from $3.16 billion in 2025 to $3.71 billion in 2026, reflecting a compound annual growth rate of 17.4%. This upward trajectory is underpinned by factors observed throughout the historical period, including diminished responsiveness to inhaled corticosteroids, an increasing incidence of asthma, the successful identification of eosinophil biomarkers, a higher number of hospital admissions for asthma-related issues, and the overall impact of chronic respiratory diseases.

    The market for eosinophilic asthma is poised for substantial expansion in the upcoming years, projected to reach $6.92 billion by 2030, driven by a compound annual growth rate of 16.9%. This anticipated surge is fueled by several key factors, including advancements in precise asthma treatment modalities, the broadening of biologic drug development pipelines, the increasing utilization of biomarker-driven diagnostic approaches, the growing emphasis on personalized respiratory care strategies, and the proliferation of specialized treatment centers. Furthermore, critical trends shaping this market over the forecast period encompass the accelerating embrace of biologic therapies, a heightened concentration on identifying and managing severe asthma phenotypes, escalating demand for immunotherapies specifically designed for targeted treatment, the continuous development of dedicated respiratory clinics, and a significant focus on mitigating the frequency of asthma exacerbations.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

    Eosinophilic Asthma Market Growth Factors Supporting Long-Term Expansion

    An increase in smoking behaviors is anticipated to be a primary driver for the expansion of the eosinophilic asthma market. These behaviors encompass the consistent patterns of tobacco product consumption, including how often, under what circumstances, and for how long individuals smoke, frequently shaped by psychological, societal, and environmental influences. Escalating smoking rates can be attributed to various elements, such as heightened stress levels, strategic promotional efforts by tobacco corporations, insufficient knowledge regarding health hazards, and the cultural acceptance of smoking in specific communities. Treatments for eosinophilic asthma, which focus on mitigating airway inflammation and enhancing respiratory capacity, can provide an impetus for individuals to quit smoking by addressing the pulmonary difficulties that often perpetuate the habit. As an illustration, data from the Office for National Statistics in the UK indicated that in November 2025, the prevalence of e-cigarette use among women in Great Britain rose from 8.5% in 2023 to 10.0% in 2024. Moreover, the highest rates of daily e-cigarette use were observed in Great Britain among individuals aged 25 to 34 and 35 to 49 years, registering 9.3% and 9.5% respectively, with an upward trend noted for both demographics from 2023. Consequently, the growing incidence of smoking is a significant factor fueling the eosinophilic asthma market.

    Eosinophilic Asthma Market Segment Landscape And Growth Potential

    The eosinophilic asthma market covered in this report is segmented –

    1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

    2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

    3) By End User: Hospitals, Clinics, Other End Users

    Subsegments:

    1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

    2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

    Eosinophilic Asthma Market Industry Trends Shaping Future Revenue Growth

    Leading entities within the eosinophilic asthma marketplace are focused on creating novel therapeutics aimed at specific immunological pathways, thereby mitigating inflammation and enhancing patient results through tailored interventions. Monoclonal antibodies are essentially engineered proteins, designed to replicate the body’s natural defense mechanisms against illnesses caused by agents like viruses and bacteria; their creation involves combining an antibody-producing cell with a cancerous cell, facilitating the mass production of identical antibodies. Highlighting this trend, AstraZeneca plc, a pharmaceutical giant from the UK, reported in August 2024 that its drug, Fasenra, had secured approval from China’s National Medical Products Administration for managing severe eosinophilic asthma. This particular therapy is designated for individuals suffering from severe eosinophilic asthma, a condition distinguished by elevated eosinophil counts, which often exacerbates asthmatic symptoms and inflammation. As a monoclonal antibody, Fasenra works by targeting and reducing eosinophils via a distinct method, strengthening the body’s immune response by attaching to the IL-5 receptor on eosinophils, which consequently lowers their concentration in both the bloodstream and bodily tissues. The administration schedule includes an initial dose escalation period followed by ongoing maintenance treatments, typically involving injections administered every four weeks for the initial three doses, after which the interval extends to every eight weeks.

    Eosinophilic Asthma Market Competitive Landscape: Who Are The Leading Companies?

    Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

    Access The Complete Eosinophilic Asthma Market Report:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Eosinophilic Asthma Market Largest Region: Which Geography Holds The Highest Market Share?

    North Americawas the largest region in the eosinophilic asthma market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Eosinophilic Asthma Market Size Projected To Increase From $3.7 Billion To $6.92 Billion During The Forecast Period

    Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

    Eosinophilic Asthma Market Size, Value And Growth Trends Through 2030

    The market for eosinophilic asthma experienced considerable expansion lately. Projections indicate a rise from $3.16 billion in 2025 to $3.71 billion in 2026, reflecting a compound annual growth rate of 17.4%. This upward trajectory is underpinned by factors observed throughout the historical period, including diminished responsiveness to inhaled corticosteroids, an increasing incidence of asthma, the successful identification of eosinophil biomarkers, a higher number of hospital admissions for asthma-related issues, and the overall impact of chronic respiratory diseases.

    The market for eosinophilic asthma is poised for substantial expansion in the upcoming years, projected to reach $6.92 billion by 2030, driven by a compound annual growth rate of 16.9%. This anticipated surge is fueled by several key factors, including advancements in precise asthma treatment modalities, the broadening of biologic drug development pipelines, the increasing utilization of biomarker-driven diagnostic approaches, the growing emphasis on personalized respiratory care strategies, and the proliferation of specialized treatment centers. Furthermore, critical trends shaping this market over the forecast period encompass the accelerating embrace of biologic therapies, a heightened concentration on identifying and managing severe asthma phenotypes, escalating demand for immunotherapies specifically designed for targeted treatment, the continuous development of dedicated respiratory clinics, and a significant focus on mitigating the frequency of asthma exacerbations.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

    Eosinophilic Asthma Market Growth Factors Supporting Long-Term Expansion

    An increase in smoking behaviors is anticipated to be a primary driver for the expansion of the eosinophilic asthma market. These behaviors encompass the consistent patterns of tobacco product consumption, including how often, under what circumstances, and for how long individuals smoke, frequently shaped by psychological, societal, and environmental influences. Escalating smoking rates can be attributed to various elements, such as heightened stress levels, strategic promotional efforts by tobacco corporations, insufficient knowledge regarding health hazards, and the cultural acceptance of smoking in specific communities. Treatments for eosinophilic asthma, which focus on mitigating airway inflammation and enhancing respiratory capacity, can provide an impetus for individuals to quit smoking by addressing the pulmonary difficulties that often perpetuate the habit. As an illustration, data from the Office for National Statistics in the UK indicated that in November 2025, the prevalence of e-cigarette use among women in Great Britain rose from 8.5% in 2023 to 10.0% in 2024. Moreover, the highest rates of daily e-cigarette use were observed in Great Britain among individuals aged 25 to 34 and 35 to 49 years, registering 9.3% and 9.5% respectively, with an upward trend noted for both demographics from 2023. Consequently, the growing incidence of smoking is a significant factor fueling the eosinophilic asthma market.

    Eosinophilic Asthma Market Segment Landscape And Growth Potential

    The eosinophilic asthma market covered in this report is segmented –

    1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

    2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

    3) By End User: Hospitals, Clinics, Other End Users

    Subsegments:

    1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

    2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

    Eosinophilic Asthma Market Industry Trends Shaping Future Revenue Growth

    Leading entities within the eosinophilic asthma marketplace are focused on creating novel therapeutics aimed at specific immunological pathways, thereby mitigating inflammation and enhancing patient results through tailored interventions. Monoclonal antibodies are essentially engineered proteins, designed to replicate the body’s natural defense mechanisms against illnesses caused by agents like viruses and bacteria; their creation involves combining an antibody-producing cell with a cancerous cell, facilitating the mass production of identical antibodies. Highlighting this trend, AstraZeneca plc, a pharmaceutical giant from the UK, reported in August 2024 that its drug, Fasenra, had secured approval from China’s National Medical Products Administration for managing severe eosinophilic asthma. This particular therapy is designated for individuals suffering from severe eosinophilic asthma, a condition distinguished by elevated eosinophil counts, which often exacerbates asthmatic symptoms and inflammation. As a monoclonal antibody, Fasenra works by targeting and reducing eosinophils via a distinct method, strengthening the body’s immune response by attaching to the IL-5 receptor on eosinophils, which consequently lowers their concentration in both the bloodstream and bodily tissues. The administration schedule includes an initial dose escalation period followed by ongoing maintenance treatments, typically involving injections administered every four weeks for the initial three doses, after which the interval extends to every eight weeks.

    Eosinophilic Asthma Market Competitive Landscape: Who Are The Leading Companies?

    Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

    Access The Complete Eosinophilic Asthma Market Report:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Eosinophilic Asthma Market Largest Region: Which Geography Holds The Highest Market Share?

    North Americawas the largest region in the eosinophilic asthma market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Eosinophilic asthma market projected to reach $6.92B by 2030 at 16.9% CAGR

    Eosinophilic asthma market projected to reach $6.92B by 2030 at 16.9% CAGR

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Does The Market Size Of The Eosinophilic Asthma Market Compare Between 2026 And 2030?

    The eosinophilic asthma market has witnessed substantial growth in recent years. It is forecast to expand from $3.16 billion in 2025 to $3.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.4%. The historical rise in this market can be attributed to elements such as poor response to inhaled steroids, an increase in asthma prevalence, the identification of eosinophil biomarkers, higher hospital asthma admissions, and the burden of chronic respiratory diseases.

    The market for eosinophilic asthma is projected to experience swift expansion over the coming years. This market is anticipated to reach $6.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.9%. Several factors contribute to this growth during the forecast period, including the advancement of precision asthma treatments, the expansion of the biologic drug pipeline, enhanced biomarker-based diagnostic methods, the provision of personalized respiratory care, and the proliferation of specialty clinics. Key trends anticipated during this period encompass the increasing acceptance of biologic therapies, a heightened focus on severe asthma phenotypes, a growing need for targeted immunotherapy, the enlargement of specialized respiratory clinics, and a stronger emphasis on mitigating exacerbation rates.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Which Drivers Are Supporting The Eosinophilic Asthma Market Growth?

    The eosinophilic asthma market is anticipated to expand due to increasing smoking habits. These habits describe consistent patterns of tobacco product use, including frequency, context, and duration, which are often shaped by psychological, social, and environmental factors. Several elements contribute to the surge in smoking habits, such as elevated stress levels, targeted marketing by tobacco companies, insufficient public awareness regarding health risks, and cultural acceptance of smoking in certain communities. Eosinophilic asthma treatment, by reducing airway inflammation and improving lung function, can also support smoking cessation by alleviating respiratory issues that often lead individuals to continue smoking. Data from November 2025, provided by the UK-based Office for National Statistics, showed an increase in e-cigarette use among women in Great Britain, rising from 8.5% in 2023 to 10.0% in 2024. Additionally, daily e-cigarette consumption was most prevalent among those aged 25 to 34 years and 35 to 49 years in Great Britain, reaching 9.3% and 9.5% respectively, with an observed increase in both age brackets since 2023. Consequently, the growing prevalence of smoking is a key driver for the eosinophilic asthma market.

    What Are The Different Segment Types In The Eosinophilic Asthma Market Segment Breakdown?

    The eosinophilic asthma market covered in this report is segmented –

    1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

    2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

    3) By End User: Hospitals, Clinics, Other End Users

    Subsegments:

    1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

    2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

    Which Trends Are Expected To Impact The Eosinophilic Asthma Market?

    Major companies within the eosinophilic asthma market are focused on developing innovative medications to target specific immune pathways, diminish inflammation, and enhance patient outcomes via individualized treatment strategies. A monoclonal antibody is a laboratory-engineered molecule designed to emulate the immune system’s capacity to combat harmful pathogens such as viruses and bacteria. These antibodies are created through a process involving the fusion of a specific antibody-producing cell with a cancerous cell, allowing for the generation of large quantities of identical antibodies. For instance, in August 2024, AstraZeneca plc, a biopharmaceutical company based in the UK, announced the approval of Fasenra by China’s National Medical Products Association, a government agency located in China, for the treatment of severe eosinophilic asthma. It is specifically prescribed for individuals with severe eosinophilic asthma, a condition marked by elevated levels of eosinophils, which can lead to inflammation and a worsening of asthma symptoms. Fasenra is a monoclonal antibody that uniquely targets and depletes eosinophils. It strengthens the immune system’s ability by binding to the IL-5 receptor on eosinophils, thereby reducing eosinophil levels in the blood and tissues. The prescribed dosing regimen comprises an initial loading phase followed by maintenance doses. Patients typically receive injections every four weeks for the first three doses, subsequently followed by injections every eight weeks.

    Who Are The Well-Known Companies In The Eosinophilic Asthma Market?

    Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

    Get The Full Eosinophilic Asthma Market Report:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Which Geographic Region Dominates The Eosinophilic Asthma Market?

    North America was the largest region in the eosinophilic asthma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Eosinophilic Asthma Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2026, By The Business Research Company

    Allergic Rhinitis Market Report 2026

    https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-global-market-report

    Anti Asthmatics And Copd Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

    Anti Asthmatics And Copd Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Eosinophilic Asthma Market Analysis for 2026–2030 with Strategic Forecast Insights for Businesses

    Global Eosinophilic Asthma Market Analysis for 2026–2030 with Strategic Forecast Insights for Businesses

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    How Large Is The Eosinophilic Asthma Market Projected To Become By 2030 Based On Its 2026 Valuation?

    The eosinophilic asthma market has experienced swift expansion recently. It is set to expand from $3.16 billion in 2025 to $3.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.4%. This historical growth can be ascribed to a poor response to inhaled steroids, an increase in asthma prevalence, the identification of eosinophil biomarkers, a rise in hospital asthma admissions, and the burden of chronic respiratory diseases.

    The eosinophilic asthma market size is anticipated to undergo significant expansion in the coming years. Its value is projected to reach $6.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.9%. This growth throughout the forecast period is attributable to the advancement of precision asthma treatment, the enlargement of the biologic drug pipeline, biomarker-based diagnosis, personalized respiratory care, and the proliferation of specialty clinics. Key trends during this period involve the increasing adoption of biologic therapies, an elevated focus on severe asthma phenotypes, a rising demand for targeted immunotherapy, the expansion of specialized respiratory clinics, and an emphasis on reducing exacerbation rates.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

    What Major Growth Drivers Are Shaping The Outlook Of The Eosinophilic Asthma Market?

    The anticipated expansion of the eosinophilic asthma market is linked to an increase in smoking habits. These habits denote consistent patterns or actions related to tobacco product consumption, encompassing the frequency, setting, and duration of smoking, frequently shaped by psychological, social, and environmental influences. The surge in smoking behaviors stems from elements like elevated stress, focused promotional efforts from tobacco firms, insufficient knowledge of associated health dangers, and the cultural normalization of smoking in specific communities. Treating eosinophilic asthma aids in diminishing airway inflammation and enhancing lung performance, potentially fostering smoking cessation by easing the breathing problems that frequently prompt individuals to persist with smoking. For example, data from November 2025, supplied by the Office for National Statistics, a UK-based government agency, indicated that the proportion of women in Great Britain reporting e-cigarette use rose from 8.5% in 2023 to 10.0% in 2024. Additionally, daily e-cigarette consumption was most prevalent among those aged 25 to 34 years and 35 to 49 years in Great Britain, at 9.3% and 9.5% respectively, showing an uptick in both age demographics since 2023. Consequently, the escalating rates of smoking are propelling the eosinophilic asthma market.

    What Segment Groups Are Identified Within The Eosinophilic Asthma Market?

    The eosinophilic asthma market covered in this report is segmented –

    1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

    2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

    3) By End User: Hospitals, Clinics, Other End Users

    Subsegments:

    1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

    2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

    What Trends Are Affecting The Expansion Of The Eosinophilic Asthma Market?

    Leading companies in the eosinophilic asthma market are developing innovative medications designed to target specific immune pathways, reduce inflammation, and enhance patient outcomes through personalized treatment options. A monoclonal antibody is a synthetic molecule created in laboratories that can mimic the immune system’s capacity to combat harmful pathogens such as viruses and bacteria. These are generated through a process involving the fusion of a particular antibody-producing cell with a cancer cell, allowing for the mass production of identical antibodies. For instance, in August 2024, AstraZeneca plc, a UK-based biopharmaceutical company, announced that Fasenra received approval from China’s National Medical Products Association, a China-based government agency, for the management of severe eosinophilic asthma. It is specifically prescribed for patients with severe eosinophilic asthma, a condition defined by elevated eosinophil levels that can result in inflammation and worsening asthma symptoms. Fasenra is a monoclonal antibody that targets and depletes eosinophils through a unique mechanism. It enhances the immune system’s capability by binding to the IL-5 receptor on eosinophils to decrease eosinophil levels in the blood and tissues. The dosing regimen includes an initial loading phase followed by maintenance doses. Patients typically receive injections every four weeks for the first three doses, and thereafter every eight weeks.

    Which Companies Hold Significant Positions In The Eosinophilic Asthma Market?

    Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

    Read the full eosinophilic asthma market report here:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Which Regions Are Projected To Dominate The Eosinophilic Asthma Market In The Coming Years?

    North America was the largest region in the eosinophilic asthma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Eosinophilic Asthma Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

    Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2026, By The Business Research Company

    Noise Vibration Harshness Testing Global Market Report

    https://www.thebusinessresearchcompany.com/report/noise-vibration-harshness-testing-global-market-report

    Cannabis Testing Global Market Report

    https://www.thebusinessresearchcompany.com/report/cannabis-testing-global-market-report

    Bioanalytical Testing Services Global Market Report

    https://www.thebusinessresearchcompany.com/report/bioanalytical-testing-services-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Eosinophilic Asthma Industry Trends and Market Forecast 2026–2030

    Global Eosinophilic Asthma Industry Trends and Market Forecast 2026–2030

    Uncover key drivers, emerging technologies, and competitive movements shaping the eosinophilic asthma market from 2026–2035 with trusted insights from The Business Research Company

    How is the Eosinophilic Asthma Market size predicted to change over the forecast window of 2026–2035?

    The eosinophilic asthma market has seen rapid expansion in recent years. It is anticipated to increase from $3.16 billion in 2025 to $3.71 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.4%. The historical growth of the market can be linked to factors such as a poor response to inhaled steroids, an increase in asthma prevalence, the identification of eosinophil biomarkers, higher hospital asthma admissions, and the burden of chronic respiratory diseases.

    The eosinophilic asthma market is anticipated to experience significant expansion over the next few years. It is projected to reach $6.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.9%. This expected growth during the forecast period is fueled by advancements in precision asthma treatments, the enlargement of the biologic drug pipeline, the implementation of biomarker-based diagnosis, the development of personalized respiratory care, and the expansion of specialty clinics. Prominent trends observed in the forecast period include the increasing uptake of biologic therapies, a heightened focus on severe asthma phenotypes, a surging demand for targeted immunotherapy, the proliferation of specialized respiratory clinics, and a strong emphasis on mitigating exacerbation rates.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

    Which Drivers Are Contributing To The Expansion Of The Eosinophilic Asthma Market?

    The anticipated increase in smoking habits is projected to drive the expansion of the eosinophilic asthma market. Smoking habits are defined as consistent patterns or actions involving tobacco product usage, including aspects like frequency, setting, and duration, frequently shaped by psychological, social, and environmental influences. This increase in smoking can be attributed to several factors, including heightened stress, focused advertising by tobacco firms, insufficient knowledge regarding health dangers, and societal acceptance of smoking in particular cultural settings. Treatment for eosinophilic asthma works by diminishing airway inflammation and enhancing lung function, thereby potentially promoting smoking cessation by easing the breathing problems that frequently compel individuals to keep smoking. For example, data from November 2025, provided by the Office for National Statistics, a UK-based government agency, showed that the proportion of women in Great Britain reporting e-cigarette use rose from 8.5% in 2023 to 10.0% in 2024. Furthermore, daily e-cigarette consumption was most prevalent among those aged 25 to 34 years and 35 to 49 years in Great Britain, reaching 9.3% and 9.5% respectively, with an observed increase in both age groups since 2023. Consequently, the escalating smoking rates are fueling the eosinophilic asthma market.

    What Segment Classifications Make Up The Eosinophilic Asthma Market?

    The eosinophilic asthma market covered in this report is segmented –

    1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

    2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

    3) By End User: Hospitals, Clinics, Other End Users

    Subsegments:

    1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

    2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

    What Trends Are Driving The Growth Trajectory Of The Eosinophilic Asthma Market?

    Leading companies within the eosinophilic asthma market are developing innovative drugs to target specific immune pathways, lessen inflammation, and improve patient outcomes through personalized treatment options. A monoclonal antibody is a synthetic molecule crafted in laboratories to mimic the immune system’s capacity to combat harmful pathogens such as viruses and bacteria. These are produced by fusing a particular antibody-producing cell with a cancer cell, allowing for the generation of large quantities of identical antibodies. For instance, in August 2024, AstraZeneca plc, a UK-based biopharmaceutical company, announced that Fasenra received approval from China’s National Medical Products Association, a China-based government agency, for the treatment of severe eosinophilic asthma. It is specifically indicated for patients with severe eosinophilic asthma, a condition characterized by high levels of eosinophils, which can lead to inflammation and worsening asthma symptoms. This is a monoclonal antibody that targets and depletes eosinophils through a unique mechanism. Fasenra enhances the immune system’s ability by binding to the IL-5 receptor on eosinophils to reduce eosinophil levels in the blood and tissues. The dosing regimen involves an initial loading phase followed by maintenance doses. Patients usually receive injections every four weeks for the first three doses, followed by every eight weeks thereafter.

    Which Key Market Players Are Investing In Expansion And Innovation Within The Eosinophilic Asthma Market?

    Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Which Region Is Expected To Experience The Fastest Growth In The Eosinophilic Asthma Market?

    North America was the largest region in the eosinophilic asthma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Eosinophilic Asthma Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

    Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2026, By The Business Research Company

    Allergic Rhinitis Market Report 2026

    https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-global-market-report

    Anti Asthmatics And Copd Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

    Anti Asthmatics And Copd Drugs Market 2026

    https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Eosinophilic Asthma Market Growth Prospects and Strategic Opportunities Through 2029

    Global Eosinophilic Asthma Market Growth Prospects and Strategic Opportunities Through 2029

    Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

    How Is The Eosinophilic Asthma Market Expected To Grow In Terms Of Size?

    The market size for eosinophilic asthma has witnessed a swift expansion in recent years. It is set to escalate from a value of $2.69 billion in 2024 to $3.16 billion in 2025, with a compound annual growth rate (CAGR) of 17.4%. Factors contributing to this growth during the historical period include an escalation in pollution levels, decreased immunity among the population, an upturn in eosinophilic asthma cases, increased prevalence of allergens and respiratory conditions, a surge in healthcare spending, as well as an enhancement in research and development activities.

    The market size of eosinophilic asthma is predicted to witness a rapid expansion in the coming years, with a projected growth to $5.95 billion in 2029 at a compound annual growth rate of 17.1%. This upward trajectory in the forecast period can be linked to the rise in respiratory diseases, increased consciousness and diagnosis rates, broadening applications for monoclonal antibodies, amplified investments in healthcare infrastructure, and the growth of personalized medicine strategies. Noteworthy trends during the forecast period comprise the advent of targeted biologics, better diagnostic instruments, bespoke treatment approaches, advanced drug delivery systems, incorporation of digital health technologies, and widened clinical trials for innovative therapies.

    Get A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

    Which Key Factors Are Fueling Growth In The Eosinophilic Asthma Market?

    The upward trend in smoking habits is anticipated to spur the eosinophilic asthma market’s expansion. The term “smoking habits” refers to the habitual use of tobacco products, including the frequency, context, and duration, which are often shaped by psychological, social, and environmental influences. The proliferation of smoking habits can be attributed to factors such as elevated stress levels, aggressive advertising strategies by tobacco firms, lack of knowledge about health repercussions, and social approval of smoking in certain societies. Treatment for eosinophilic asthma, which diminishes airway inflammation and enhances lung function, may promote smoking cessation by addressing the respiratory problems that frequently compel individuals to persist with smoking. For example, the National Health Service, a UK governmental body, revealed in December 2023 that hospital admissions due to smoking had risen to around 408,700 in 2022–23 from 389,800 in 2021–22, marking a 4.8% surge. Consequently, the increased incidence of smoking propels the growth of the eosinophilic asthma market.

    How Is The Eosinophilic Asthma Market Categorized Across Applications And Types?

    The eosinophilic asthmamarket covered in this report is segmented –

    1) By Disease: Severe Eoisnophilic Asthma; Mild To Moderate Eosinophilic Asthma

    2) By Treatment: Biologics; Bronchodilators; Corticosteroids; Immunomodulators; Other Treatments

    3) By End User: Hospitals; Clinics; Other End Users

    Subsegments:

    1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma; Late-Onset Eosinophilic Asthma

    2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma; Intermittent Eosinophilic Asthma

    How Are Market Trends Influencing Competition In The Eosinophilic Asthma Market?

    Major companies in the eosinophilic asthma market are working on novel drugs that target specific immune pathways to reduce inflammation and offer personalized treatment to improve patient outcomes. Monoclonal antibodies—lab-created molecules that mimic the immune system’s pathogen-fighting ability—are produced by merging antibody-producing cells with cancer cells, allowing large-scale production of identical antibodies. For instance, in August 2024, UK-based biopharmaceutical company AstraZeneca plc announced that its drug Fasenra received approval from China’s National Medical Products Administration for treating severe eosinophilic asthma. Designed for patients with elevated eosinophil levels, Fasenra is a monoclonal antibody that binds to the IL-5 receptor on eosinophils to reduce their presence in blood and tissues. The treatment includes an initial loading phase with injections every four weeks for the first three doses, followed by maintenance doses every eight weeks.

    Which Firms Are Making The Biggest Impact In The Eosinophilic Asthma Market?

    Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

    Access The Complete Report Here:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Which Region Holds The Greatest Opportunity For Eosinophilic Asthma Market Expansion?

    North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Customize Your Report Here:

    https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

    Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2025, By The Business Research Company

    Anti Asthmatics And Copd Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

    Asthma Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

    Autoimmune Disease Diagnosis Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Eosinophilic Asthma Industry Anticipated to Expand at 17.1% CAGR During the Forecast Period

    Eosinophilic Asthma Industry Anticipated to Expand at 17.1% CAGR During the Forecast Period

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Are The Forecasted Market Size Estimates For The Eosinophilic Asthma Market Between 2025 And 2029?

    The eosinophilic asthma market size has seen rapid growth in recent years. It is forecast to expand from $2.69 billion in 2024 to $3.16 billion in 2025, achieving a compound annual growth rate (CAGR) of 17.4%. The historical period’s expansion can be ascribed to several factors, including an increase in pollution, lower immunity in the population, a rise in the prevalence of eosinophilic asthma, an increase in the prevalence of allergens and respiratory conditions, a rise in healthcare expenditure, and an uptick in R&D activities.

    The eosinophilic asthma market is projected to experience substantial growth in the upcoming years. It is expected to expand to $5.95 billion by 2029, achieving a compound annual growth rate (CAGR) of 17.1%. This expansion during the forecast period can be attributed to the increasing incidence of respiratory conditions, enhanced awareness and improved diagnosis rates, broader therapeutic uses for monoclonal antibodies, increased investment in healthcare infrastructure, and the growing adoption of personalized medicine techniques. Significant trends anticipated in this period encompass the creation of targeted biologics, advancements in diagnostic instruments, individualized treatment strategies, improved drug delivery systems, the integration of digital health technologies, and an increase in clinical trials for innovative therapies.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

    What Are The Drivers Pushing New Developments In The Eosinophilic Asthma Market?

    The anticipated rise in smoking habits is expected to drive the expansion of the eosinophilic asthma market in the future. Smoking habits refer to consistent behaviors or patterns involving the consumption of tobacco products, such as how often, where, and for how long individuals smoke, often influenced by psychological, social, and environmental factors. This increase in smoking can be attributed to factors like heightened stress levels, strategic marketing by tobacco companies, insufficient understanding of health risks, and the social normalization of smoking in certain communities. Eosinophilic asthma treatment helps mitigate airway inflammation and enhance lung function, which can support smoking cessation by easing the respiratory issues that frequently motivate patients to continue smoking. As an illustration, in December 2023, the National Health Service, a UK-based government department, reported an estimated 408,700 hospital admissions attributed to smoking in 2022–23, an increase of 4.8% from 389,800 admissions in 2021–22. Consequently, the escalating smoking rates are a key driver for the eosinophilic asthma market.

    What Are The Key Segments In The Eosinophilic Asthma Market?

    The eosinophilic asthmamarket covered in this report is segmented –

    1) By Disease: Severe Eoisnophilic Asthma; Mild To Moderate Eosinophilic Asthma

    2) By Treatment: Biologics; Bronchodilators; Corticosteroids; Immunomodulators; Other Treatments

    3) By End User: Hospitals; Clinics; Other End Users

    Subsegments:

    1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma; Late-Onset Eosinophilic Asthma

    2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma; Intermittent Eosinophilic Asthma

    What Trends Are Expected To Drive The Eosinophilic Asthma Market?

    Leading firms in the eosinophilic asthma sector are creating novel medications designed to target specific immunological pathways, lessen inflammation, and enhance patient results via tailored therapeutic approaches. Monoclonal antibodies are lab-engineered molecules capable of replicating the immune system’s defense against dangerous pathogens like viruses and bacteria, produced by merging an antibody-generating cell with a cancer cell to yield numerous identical antibodies. As an illustration, in August 2024, AstraZeneca plc, a biopharmaceutical company based in the UK, revealed the approval of Fasenra by China’s National Medical Products Association, a Chinese governmental body, for treating severe eosinophilic asthma. This medication is specifically prescribed for individuals suffering from severe eosinophilic asthma, a condition marked by elevated eosinophil counts, which often results in inflammation and intensified asthma symptoms. It functions as a monoclonal antibody that uniquely targets and reduces eosinophil levels. Fasenra boosts the immune system’s efficacy by attaching to the IL-5 receptor on eosinophils, thereby decreasing eosinophil concentrations in both blood and tissues. Its dosing schedule includes an initial loading phase, followed by subsequent maintenance doses. Typically, patients receive injections every four weeks for the initial three doses, and then every eight weeks subsequently.

    Who Are The Top Performing Companies In The Eosinophilic Asthma Market In Recent Years?

    Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Which Global Regions Are Influencing The Competitive Landscape Of The Eosinophilic Asthma Market?

    North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Eosinophilic Asthma Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

    Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2025, By The Business Research Company

    Anti Asthmatics And Copd Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

    Asthma Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

    Autoimmune Disease Diagnosis Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Eosinophilic Asthma Industry Insights 2025 – Market Forecast for Executives and Planners

    Eosinophilic Asthma Industry Insights 2025 – Market Forecast for Executives and Planners

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Eosinophilic Asthma Market Size Changed, over the years?

    The market size for eosinophilic asthma has experienced swift expansion in recent times. Projected to escalate from $2.69 billion in 2024 to $3.17 billion in 2025, the compound annual growth rate (CAGR) stands at 17.7%. The escalation during the historic period can be linked to factors such as increased pollution, reduced immunity in population, burgeoning prevalence of eosinophilic asthma, heightened occurrence of allergens and respiratory conditions, increased expenditure in healthcare, and uptick in research and development activities.

    How Much Will the Eosinophilic Asthma Market Be Worth in 2029?

    The market size for eosinophilic asthma is predicted to grow swiftly in the forthcoming years, reaching a value of $6.01 billion in 2029 with a compound annual growth rate (CAGR) of 17.4%. This growth in the projected period is expected due to the heightened prevalence of respiratory diseases, rising levels of awareness and diagnosis, the extension of therapeutic applications for monoclonal antibodies, increased investment in healthcare infrastructure, and the emergence of personalised medicine strategies. Key trends in this predicted period are the creation of targeted biologics, the improvement of diagnostic instruments, personalisation of treatment methods, improved drug delivery mechanisms, the incorporation of digital health technology, and increased clinical trials for new therapies.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

    Which is the Largest Company in the Eosinophilic Asthma Market?

    Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

    What Are the Main Market Drivers in the Eosinophilic Asthma Industry?

    The eosinophilic asthma market is projected to grow due to the increased prevalence of smoking habits. These habits, which entail frequent and patterned use of tobacco products, are often shaped by various psychological, social, and environmental influences. The surge in these habits can be attributed to heightened stress levels, targeted tobacco advertising, lack of knowledge regarding health dangers, and the social endorsement of smoking within some cultures. By lessening airway inflammation and boosting lung function, treatment for eosinophilic asthma can promote quitting smoking by easing the respiratory difficulties that often compel patients to persist with this habit. For example, the National Health Service, a government department in the UK, reported in December 2023 that hospital admissions due to smoking rose from 389,800 in 2021-22 to an estimated 408,700 in 2022–23, marking a 4.8% increase. As a consequence of escalating smoking rates, the market for eosinophilic asthma is expected to thrive.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

    How Is the Eosinophilic Asthma Market Segments Structured?

    The eosinophilic asthma market covered in this report is segmented –

    1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

    2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

    3) By End User: Hospitals, Clinics, Other End Users

    Subsegments:

    1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

    2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

    What Strategic Trends Are Transforming the Eosinophilic Asthma Market?

    Leading business entities within the eosinophilic asthma market are focusing on the creation of novel medications tailored to individual immune pathway targets, aimed at minimising inflammation and enhancing patient prognosis via personalised treatment strategies. Laboratory-produced monoclonal antibodies are manufactured in a way that simulates the immune system’s capacity to combat harmful pathogens, including bacteria and viruses. This involves the fusion of a specific antibody-producing cell with a cancerous cell, thereby facilitating the large-scale production of identical antibodies. In an illustration of this pattern, AstraZeneca plc, a biopharmaceutical firm based in the UK, announced in August 2024 that Fasenra, their product, had gained approval from the National Medical Products Association in China. This government agency greenlighted the drug for the treatment of severe eosinophilic asthma, a disorder characterised by heightened eosinophil levels resulting in inflammation and escalating asthma symptoms. Fasenra is a monoclonal antibody that operates by targeting and reducing the number of eosinophils, using a distinct mechanism. In terms of ameliorating the immune system function, Fasenra works by linking to the IL-5 receptor on eosinophils, effectively decreasing these cells’ levels in blood and tissue. The dosage protocol generally starts with an initial loading phase, followed by subsequent maintenance doses. Regular treatment involves injections, usually every four weeks for the first three doses, with bi-monthly doses thereafter.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    Which Global Regions Offer the Highest Growth in the Eosinophilic Asthma Market?

    North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21184

    This Report Delivers Insight On:

    1. How big is the eosinophilic asthma market, and how is it changing globally?

    2. Who are the major companies in the eosinophilic asthma market, and how are they performing?

    3. What are the key opportunities and risks in the eosinophilic asthma market right now?

    4. Which products or customer segments are growing the most in the eosinophilic asthma market?

    5. What factors are helping or slowing down the growth of the eosinophilic asthma market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 2071930708

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Major Trends and Emerging Patterns in the Eosinophilic Asthma Market: Advancements In Targeted Therapies For Severe Asthma Management

    Major Trends and Emerging Patterns in the Eosinophilic Asthma Market: Advancements In Targeted Therapies For Severe Asthma Management

    Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

    What Are the Key Projections for the CAGR of the Eosinophilic Asthma Market Size From 2025 to 2034?

    The market size for eosinophilic asthma has seen substantial growth in recent times. It is set to rise from $2.69 billion in 2024 to $3.17 billion in 2025, with a compound annual growth rate (CAGR) of 17.7%. The expansion during the historic period can be linked to the increase in pollution, a decrease in population immunity, a surge in the occurrence of eosinophilic asthma, a rise in allergens and respiratory conditions, an increase in healthcare spending, and an elevation in research and development activities.

    In the upcoming years, the eosinophilic asthma market is set to experience accelerated growth. It is predicted to expand to a worth of $6.01 billion by 2029, displaying a compound annual growth rate (CAGR) of 17.4%. This growth over the projection period can be linked to several factors, including the rising prevalence of respiratory illnesses, greater awareness and diagnosis rates, broadening applications for monoclonal antibodies, increased healthcare infrastructure investment, and an upsurge in bespoke medical approaches. Noteworthy trends for this forecasted period encompass the establishment of targeted biologics, advancement in diagnostic tools, tailored treatment methods, bolstered drug delivery systems, merging with digital health technologies, and augmented clinical trials for new therapies.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

    What Are the Primary Drivers Supporting the Market Growth of the Eosinophilic Asthma Market?

    The growth of the eosinophilic asthma market is propelled by increasing smoking habits. The term ‘smoking habits’ encompasses regular usage and patterns of tobacco consumption, including the frequency, context, and duration of smoking, which are generally influenced by psychological, social, and environmental factors. The increase in smoking habits can be attributed to factors such as elevated stress levels, targeted advertising campaigns by tobacco manufacturers, lack of understanding of health-related risks, and the social acceptance of smoking in specific cultures. Eosinophilic asthma treatment reduces airway inflammation and improves lung function, which can promote smoking cessation by easing the respiratory complications that often compel patients to keep smoking. For example, in December 2023, the National Health Service, a UK-based government agency, reported an estimated 408,700 hospital admissions due to smoking in 2022–23, which is an increase of 4.8% from 389,800 in 2021–22. Hence, the escalating smoking rates contribute towards the growth of the eosinophilic asthma market.

    Which Primary Segments of the Eosinophilic Asthma Market Are Driving Growth and Industry Transformations?

    The eosinophilic asthma market covered in this report is segmented –

    1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

    2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

    3) By End User: Hospitals, Clinics, Other End Users

    Subsegments:

    1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

    2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

    Which Regions Are Key Players in the Growth of the What Are the Primary Drivers Supporting the Market Growth of the Eosinophilic Asthma Market? Market?

    North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Most Significant Market Trends in the Eosinophilic Asthma Market?

    Key players in the eosinophilic asthma market are focusing on the creation of novel drugs to specifically target immune pathways, reduce inflammation, and better the results of patient treatment through individualized treatments. One such method involves the use of monoclonal antibodies, which are essentially laboratory-created molecules that replicate the immune system’s ability to combat harmful viruses and bacteria. The creation of these antibodies involves merging a specific antibody-producing cell with a cancer cell, thus allowing for the mass production of identical antibodies. For example, in August 2024, AstraZeneca plc, a biopharmaceutical firm based in the UK, made public the approval of Fasenra by the China’s National Medical Products Association for the treatment of severe eosinophilic asthma. The condition, severe eosinophilic asthma, is distinguished by high eosinophil counts which can trigger inflammation and an exacerbation of asthma symptoms. Fasenra, a monoclonal antibody, aims to target and eliminate eosinophils using a distinctive mechanism. By latching onto the IL-5 receptor on eosinophils, Fasenra can boost the immune system’s capability and lower eosinophil levels in blood and tissue. The treatment regimen starts with a loading phase before transitioning to maintenance doses. Generally, patients receive injections every four weeks for the first three doses, with the frequency reducing to every eight weeks subsequently.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

    What Parameters Are Used to Define the Eosinophilic Asthma Market?

    Eosinophilic asthma is a form of asthma where high eosinophil counts, a specific white blood cell type, cause airway inflammation. This condition results in severe symptoms such as breathing issues and recurring flare-ups, with limited effectiveness from standard treatments such as inhaled steroids.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21184

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model